CN103768251B - 一种杀灭血液细胞中病毒、提高人体抗体免疫力的药物 - Google Patents
一种杀灭血液细胞中病毒、提高人体抗体免疫力的药物 Download PDFInfo
- Publication number
- CN103768251B CN103768251B CN201410064506.9A CN201410064506A CN103768251B CN 103768251 B CN103768251 B CN 103768251B CN 201410064506 A CN201410064506 A CN 201410064506A CN 103768251 B CN103768251 B CN 103768251B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- syphilis
- borneol
- aids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 110
- 241000700605 Viruses Species 0.000 title claims abstract description 26
- 210000000601 blood cell Anatomy 0.000 title claims abstract description 20
- 230000003053 immunization Effects 0.000 title abstract 3
- 208000006379 syphilis Diseases 0.000 claims abstract description 42
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 208000030507 AIDS Diseases 0.000 claims abstract description 31
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 25
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229940116229 borneol Drugs 0.000 claims abstract description 23
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 23
- ZOMNIUBKTOKEHS-UHFFFAOYSA-L dimercury dichloride Chemical compound Cl[Hg][Hg]Cl ZOMNIUBKTOKEHS-UHFFFAOYSA-L 0.000 claims abstract description 23
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 23
- 230000002147 killing effect Effects 0.000 claims abstract description 22
- 229940075397 calomel Drugs 0.000 claims abstract description 20
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 19
- 241001448862 Croton Species 0.000 claims abstract description 8
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 7
- 230000036039 immunity Effects 0.000 claims description 30
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 20
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 20
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 20
- 235000006533 astragalus Nutrition 0.000 claims description 17
- 241000045403 Astragalus propinquus Species 0.000 claims description 10
- 206010013663 drug dependence Diseases 0.000 claims description 4
- 244000182216 Mimusops elengi Species 0.000 claims 5
- 244000274050 Platycodon grandiflorum Species 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 19
- 201000010099 disease Diseases 0.000 abstract description 17
- 240000003582 Platycodon grandiflorus Species 0.000 abstract description 14
- 244000241838 Lycium barbarum Species 0.000 abstract description 9
- 235000015459 Lycium barbarum Nutrition 0.000 abstract description 9
- 239000009636 Huang Qi Substances 0.000 abstract description 5
- 206010013654 Drug abuse Diseases 0.000 abstract description 3
- 208000011580 syndromic disease Diseases 0.000 abstract description 3
- 244000025254 Cannabis sativa Species 0.000 abstract 2
- 229940079593 drug Drugs 0.000 description 35
- 230000000694 effects Effects 0.000 description 32
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 206010012735 Diarrhoea Diseases 0.000 description 16
- 231100000331 toxic Toxicity 0.000 description 16
- 230000002588 toxic effect Effects 0.000 description 16
- 240000002624 Mespilus germanica Species 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 15
- 244000168525 Croton tiglium Species 0.000 description 14
- 241000725303 Human immunodeficiency virus Species 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 206010037660 Pyrexia Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 9
- 230000036737 immune function Effects 0.000 description 9
- 239000006187 pill Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 208000026435 phlegm Diseases 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 241001061264 Astragalus Species 0.000 description 7
- 208000006083 Hypokinesia Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 210000004233 talus Anatomy 0.000 description 7
- 239000003053 toxin Substances 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 230000008673 vomiting Effects 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- WCASXYBKJHWFMY-UHFFFAOYSA-N gamma-methylallyl alcohol Natural products CC=CCO WCASXYBKJHWFMY-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 5
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 5
- 235000015468 Lycium chinense Nutrition 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 206010048010 Withdrawal syndrome Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 229960002069 diamorphine Drugs 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 230000003405 preventing effect Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 229940126680 traditional chinese medicines Drugs 0.000 description 5
- WCASXYBKJHWFMY-NSCUHMNNSA-N 2-Buten-1-ol Chemical compound C\C=C\CO WCASXYBKJHWFMY-NSCUHMNNSA-N 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000001490 Opioid Peptides Human genes 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000003399 opiate peptide Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 210000004916 vomit Anatomy 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 3
- 208000008306 Latent Syphilis Diseases 0.000 description 3
- 244000241872 Lycium chinense Species 0.000 description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 3
- 108010093625 Opioid Peptides Proteins 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 235000005473 carotenes Nutrition 0.000 description 3
- 150000001746 carotenes Chemical class 0.000 description 3
- -1 crotyl alcohol diester Chemical class 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 208000026500 emaciation Diseases 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- PLAPMLGJVGLZOV-UHFFFAOYSA-N Epi-orientin Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O PLAPMLGJVGLZOV-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010023644 Lacrimation increased Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000589884 Treponema pallidum Species 0.000 description 2
- 241000218989 Trichosanthes Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 244000126002 Ziziphus vulgaris Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000006901 congenital syphilis Diseases 0.000 description 2
- 229940117173 croton oil Drugs 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000004317 lacrimation Effects 0.000 description 2
- 235000011477 liquorice Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 235000019633 pungent taste Nutrition 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- PETSAYFQSGAEQY-UHFFFAOYSA-N ricinine Chemical compound COC=1C=CN(C)C(=O)C=1C#N PETSAYFQSGAEQY-UHFFFAOYSA-N 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- ODBRNZZJSYPIDI-UHFFFAOYSA-N 3',4',5,7-tetrahydroxy-6-C-glucopyranosylflavone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=C(OC(=CC2=O)C=3C=C(O)C(O)=CC=3)C2=C1O ODBRNZZJSYPIDI-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000545417 Aleurites Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000003717 Boswellia sacra Nutrition 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 235000004415 Burchellia bubalina Nutrition 0.000 description 1
- 240000008537 Burchellia bubalina Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001161070 Calomela Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 244000293323 Cosmos caudatus Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- 241000234276 Curculigo Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010013886 Dysaesthesia Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 244000062748 Eupatorium adenophorum Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000555682 Forsythia x intermedia Species 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 206010051602 Laziness Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- PTNJRKBWIYNFSY-UHFFFAOYSA-N Lirinin-O-methyl-ether Natural products COc1ccc-2c(CC3N(C)CCc4cc(OC)c(OC)c-2c34)c1 PTNJRKBWIYNFSY-UHFFFAOYSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 108070000021 Opioid peptides receptors Proteins 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- RBVAFYCFAFADAG-UHFFFAOYSA-N Orientin Natural products OCC1OC(C(O)c2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)c(O)c4)C(O)C1O RBVAFYCFAFADAG-UHFFFAOYSA-N 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 235000003713 Rhodiola rosea Nutrition 0.000 description 1
- 244000042430 Rhodiola rosea Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 201000000860 Secondary syphilis Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- WJJFWGUVMIUWGG-UHFFFAOYSA-N Stereolensin Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(OC(=CC2=O)C=3C=C(O)C(O)=CC=3)C2=C1O WJJFWGUVMIUWGG-UHFFFAOYSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 240000006688 Telosma cordata Species 0.000 description 1
- 235000017352 Telosma cordata Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 241001480050 Trichophyton violaceum Species 0.000 description 1
- LQSNPVIQIPKOGP-UHFFFAOYSA-N UNPD159785 Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O LQSNPVIQIPKOGP-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 240000001866 Vernicia fordii Species 0.000 description 1
- 240000006917 Vernicia montana Species 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229910052956 cinnabar Inorganic materials 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 206010013395 disorientation Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- ODBRNZZJSYPIDI-VJXVFPJBSA-N isoorientin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC(=CC2=O)C=3C=C(O)C(O)=CC=3)C2=C1O ODBRNZZJSYPIDI-VJXVFPJBSA-N 0.000 description 1
- UYJGIAWJIRZBNU-UHFFFAOYSA-N isoorientin Natural products OCC1OC(C(O)C(O)C1O)c2cc(O)c(O)c3C(=O)C=C(Oc23)c4ccc(O)c(O)c4 UYJGIAWJIRZBNU-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000011977 language disease Diseases 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000019569 negative regulation of cell differentiation Effects 0.000 description 1
- PEFNSGRTCBGNAN-UHFFFAOYSA-N nephrocizin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 PEFNSGRTCBGNAN-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- PLAPMLGJVGLZOV-VPRICQMDSA-N orientin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=CC2=O PLAPMLGJVGLZOV-VPRICQMDSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Inorganic materials [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000009090 primary syphilis Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 206010056873 tertiary syphilis Diseases 0.000 description 1
- 208000001644 thecoma Diseases 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 description 1
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于医药领域,具体为一种杀灭血液细胞中病毒、提高人体抗体免疫力的药物。该药物的组成及含量为:按重量份数计,黄芪1~5份;桔梗1~5份;枸杞1~5份;红枣1~5份;冰片1~5份;巴豆1~2份;败毒草1~2份;轻粉1~2份。本发明采用黄芪、桔梗、枸杞、红枣、冰片、巴豆、败毒草、轻粉组合为一个整体,相互之间配合使用,通过杀灭血液细胞中病毒、提高人体抗体免疫力,可以有效地治疗艾滋病、梅毒、吸毒等疾病。
Description
技术领域
本发明属于医药领域,具体为一种杀灭血液细胞中病毒、提高人体抗体免疫力的药物。
背景技术
艾滋病(AIDS)是一种危害性极大的传染病,由感染艾滋病病毒(HIV病毒)引起,HIV是一种能攻击人体免疫***的病毒。它把人体免疫***中最重要的T淋巴细胞作为主要攻击目标,大量破坏该细胞,使人体丧失免疫功能。因此,人体易于感染各种疾病,并可发生恶性肿瘤,病死率较高。HIV在人体内的潜伏期平均为8~9年,患艾滋病以前,可以没有任何症状地生活和工作多年。HIV感染者要经过数年、甚至长达10年或更长的潜伏期后才会发展成艾滋病病人,因机体抵抗力极度下降会出现多种感染,如:带状疱疹、口腔霉菌感染、肺结核,特殊病原微生物引起的肠炎、肺炎、脑炎,念珠菌、肺孢子虫等多种病原体引起的严重感染等,后期常常发生恶性肿瘤,并发生长期消耗,以至全身衰竭而死亡。虽然全世界众多医学研究人员付出了巨大的努力,但至今尚未研制出根治艾滋病的特效药物,也还没有可用于预防的有效疫苗。艾滋病已被我国列入乙类法定传染病,并被列为国境卫生监测传染病之一。
梅毒是由苍白(梅毒)螺旋体引起的慢性、***性性传播疾病。主要通过性途径传播,临床上可表现为一期梅毒、二期梅毒、三期梅毒、潜伏梅毒和先天梅毒(胎传梅毒)等。在《中华人民共和国传染病防治法》中,列为乙类防治管理的病种。梅毒在全世界流行,据WHO估计,全球每年约有1200万新发病例,主要集中在南亚、东南亚和次撒哈拉非洲。近年来梅毒在我国增长迅速,已成为报告病例数最多的性病。所报告的梅毒中,潜伏梅毒占多数,一、二期梅毒也较为常见,先天梅毒报告病例数也在增加。梅毒患者的皮肤、黏膜中含***,未患病者在与梅毒患者的性接触中,皮肤或黏膜若有细微破损则可得病,极少数可通过输血或途径传染,获得性梅毒(后天)早期梅毒病人是传染源,95%以上是通过危险的或无保护的性行为传染,少数通过接亲吻、输血、污染的衣物等传染。胎传梅毒由患梅毒的孕妇传染,如果一、二期和早期潜伏梅毒的孕妇,传染给胎儿的几率相当高。
目前,流行最广、危害最严重的毒品是***,***属于阿片酊药物。在正常人的脑内和体内一些器官,存在着内源性阿片肽和阿片受体。在正常情况下,内源性阿片肽作用于阿片受体,调节着人的情绪和行为。人在吸食***后,抑制了内源性阿片肽的生成,逐渐形成在***作用下的平衡状态,一旦停用就会出现不安、焦虑、忽冷忽热、起鸡皮疙瘩、流泪、流涕、出汗、恶心、呕吐、腹痛、腹泻等症状。这种戒断反应的痛苦,反过来又促使吸毒者为避免这种痛苦而千方百计地维持吸毒状态。***和***在药理作用上属中枢兴奋药,毁坏人的神经中枢。毒品的危害可以说有很多,如:
(1)吸毒对身体的毒性作用:毒性作用是指用药剂量过大或用药时间过长引起的对身体的一种有害作用,通常伴有机体的功能失调和组织病理变化。中毒主要特征有:嗜睡、感觉迟钝、运动失调、幻觉、妄想、定向障碍等。
(2)戒断反应:是长期吸毒造成的一种严重和具有潜在致命危险的身心损害,通常在突然终止用药或减少用药剂量后发生。许多吸毒者在没有经济来源购毒、吸毒的情况下,或死于严重的身体戒断反应引起的各种并发症,或由于痛苦难忍而***身亡。戒断反应也是吸毒者戒断难的重要原因。
(3)精神障碍与***:吸毒所致最突出的精神障碍是幻觉和思维障碍。他们的行为特点围绕毒品转,甚至为吸毒而丧失人性。
(4)感染性疾病:静脉注射毒品给滥用者带来感染性合并症,最常见的有化脓性感染和乙型肝炎,及令人担忧的艾滋病问题。此外,吸毒还会损害神经***、免疫***,易感染各种疾病。
中药戒毒具有悠久的历史,18世纪末的中国即有中药戒毒的运用,并已形成一套完善的理论:健康的机体阴阳平衡、气血充盈。而毒品进入人体后,损耗脾肾的阴气,引起阴阳失调、气血亏损,造成湿浊内生,全身各通路堵塞,进而阻塞心窍,完全损害大脑,所以吸毒症表现为全身各种功能全部失调。要达到成戒毒的目的,就要调节阴阳、通心窍。中国古代的医学在戒毒方面积累了丰富而宝贵的经验,清代的禁烟英雄林则徐即是其中一例。中药类戒毒药的使用早在我国18世纪末就已开始,当时应用最广的有戒烟丸、忌酸丸和补正丸。
关于艾滋病、梅毒的专利很多,例如:
中国发明专利(专利号:03153879.7)公开了一种根治梅毒中成药丸剂及制备方法,产品配方是,臧红花、灵芝草、金银花、轻粉、蛇胆、乳香、没药、枸杞、明矾;产品制备工艺是,将上述配方中药材经过精选,烘干过筛捣拌研磨成粉状合一拌均,然后用煮沸冷却到10~20摄氏度的优质100~300克蜂蜜进行合成丸剂即特九丹中成药。该发明杀菌攻毒、消淤抗痈肿、止痛生肌、养血的作用,是临床治疗确保身心健康、根除梅菌恶症、根除遗传性因子,疗程短,经济实惠,快速治愈梅毒病症,永不反弹。
中国发明专利(专利号:93103950.9)公开了一种梅毒、淋病一次清及其制造方法,该药包括:龙胆草、当归、泽泻、桅子、木通、车前子、黄芩、防风、土茯苓、银花、熟地、党参、黄芪、山萸肉、枸杞子、川芎、木瓜、大黄、猪苦胆、白蜜及珍珠,它们以一定份额制成丸药。该药具有用药方便,治病迅速,可治愈多种疾病的优点,所治疾病还包括:***、生殖器疱疹、非淋病性尿道炎及***。
中国发明专利(专利号:200810058190.7)公开了一种治疗梅毒病的药物及其制备方法,按重量计由冰片6至9份,白矾6到9份,丹砂3至5份,水银2至4份,硇砂4至6份,硝石4至6份制成。该药物的制作方法是:将原料放入锅内,用新瓷碗扣住并密封放入锅中,在小火上烧制30至50分钟,再用大火烧制90至110分钟,待锅冷却后收集碗中药粉而成。该药物毒副作用较小,使用方便,治疗时间短而且疗效较明显,成本低。
中国发明专利(专利号:200910223778.8)公开了一种治疗艾滋病的中药组合物及其制备方法,该中药组合物由如下重量份的原料药组成:人参300~400、三七200~300、天花粉120~220、青黛120~220、水牛角粉10~25、紫花地丁120~220、地龙120~220、儿茶100~200、冰片10~25、甘草120~220。该中药组合物能升高CD4淋巴细胞计数,对HIV病毒具有一定的抑制作用,对艾滋病患者的乏力、低热、消瘦、咳嗽、纳呆等症状有较好效果,其中对乏力和咳嗽的治疗效果非常显著。
中国发明专利(专利号:200510045682.9)公开了一种治疗艾滋病的中药,原料组分及重量比例是:当归0.6~1.5;黄芪1.6~2.5;枸杞子1.6~2.5;黄芩1.6~2.5;天花粉1.6~2.5;苦参1.6~2.5;黄牛胆0.6~1.5;甘草1.6~2.5;红景天1.6~2.5;女真子0.6~1.5;冠叶连翘1.6~2.5;五爪金龙1.6~2.5。与现有技术比较具有如下的优点:毒副作用小,服用安全方便,能显著提高艾滋病患者的机体免疫力,降低外周血病毒载量,有效改善临床症状,控制病情发展,提高生活质量。
中国发明专利(专利号:200810180466.9)公开了一种抗艾滋病的中药复方组合物及其制备方法,采用鹿茸、枸杞子、淫羊藿、仙茅、肉苁蓉等中药原料经提取、浓缩、煎煮、过滤、浓缩、真空干燥、粉碎、混合后制成的抗艾滋病中药复方组合物。其功能是主治艾滋病和艾滋病毒感染者,不仅能抑制和杀灭艾滋病病毒,而且能提高人体免疫力,升高人体CD4细胞,从而消除病人的全部症状,恢复病人的体力与体重,使之健康地生活和工作。
我国中医的历史悠久,中药宝库的丰富,能否挖掘出对艾滋病、梅毒、吸毒等效果更好、无副作用的中药,至今仍然是人们需要不断探索的课题。
发明内容
本发明的目的在于提供一种杀灭血液细胞中病毒、提高人体抗体免疫力的药物,采用纯天然的中药,对治疗艾滋病、梅毒、吸毒等效果好。
本发明的技术方案是:
一种杀灭血液细胞中病毒、提高人体抗体免疫力的药物,该药物的组成及含量为:
按重量份数计,黄芪1~5份;桔梗1~5份;枸杞1~5份;红枣1~5份;冰片1~5份;巴豆1~2份;败毒草1~2份;轻粉1~2份。
所述的杀灭血液细胞中病毒、提高人体抗体免疫力的药物,该药物的组成及含量优选为:
按重量份数计,黄芪1~3份;桔梗1~3份;枸杞1~3份;红枣1~3份;冰片1~3份;巴豆1~2份;败毒草1~2份;轻粉1~2份。
所述的杀灭血液细胞中病毒、提高人体抗体免疫力的药物,该药物用于治疗艾滋病,其组成及含量为:
按重量份数计,黄芪1~2份;桔梗1~2份;枸杞1~2份;红枣1~2份;冰片1~3份;巴豆1~2份;败毒草1~2份;轻粉1~2份。
所述的杀灭血液细胞中病毒、提高人体抗体免疫力的药物,该药物用于治疗梅毒,其组成及含量为:
按重量份数计,黄芪1~2份;桔梗1份;枸杞1~3份;红枣1~2份;冰片1~3份;巴豆1~2份;败毒草1~2份;轻粉1~2份。
所述的杀灭血液细胞中病毒、提高人体抗体免疫力的药物,该药物用于治疗吸毒,其组成及含量为:
按重量份数计,黄芪1~3份;桔梗1~2份;枸杞1~3份;红枣1~2份;冰片1~2份;巴豆1~2份;败毒草1~2份;轻粉1~2份。
本发明所用中药的药理如下:
黄芪:味甘,性温,有提神、敛汗固表、托疮排毒生肌的功效,将疮毒排出体外,在疮疡的溃***生长新的组织,作为治疗气虚证的主药,亦用于气血不足所致痈疽久不溃破或溃久不敛等证,可促使邪毒外泄,促进肌肉生长。
桔梗:味苦、辛,微温,能化痰利咽,开胸利壅,善治风热、风寒、痰湿之咳嗽,以及胸闷不适、肺痈、咽喉肿痛等。并且,能载药上行,使药物通过肺的敷布而发挥作用,提高免疫力。
枸杞:味甘,性温,能补精益髓,明目祛风,可用于肝肾亏虚所致头昏目暗、腰膝酸软等病证,对免疫功能有影响作用。枸杞子含枸杞多糖、枸杞色素,其中:
(1)枸杞多糖:枸杞多糖是一种水溶性多糖,是枸杞中最主要的活性成分,相对分子质量为68~200,成为国内外研究热点。其中又以枸杞多糖的免疫调节和抗肿瘤作用的研究最多。现已有很多研究表明枸杞多糖具有促进免疫、抗衰老、抗肿瘤、清除自由基、抗疲劳、抗辐射、保肝、生殖功能保护和改善等作用。
(2)枸杞色素是存在于枸杞浆果中的各类呈色物质,是枸杞籽的重要生理活性成分。主要包括-胡萝卜素、叶黄素和其他有色物质。枸杞所含有的类胡萝卜素则具有非常重要的药用价值。很多研究已经证明枸杞籽色素具有提高人体免疫功能、预防和抑制肿瘤及预防动脉粥样硬化等作用。胡萝卜素是枸杞色素的主要活性成分,具有抗氧化和作为维生素A的合成前体等重要的生理功能。
红枣,又名大枣。味甘,性温,能调和百药,并有益气健脾、补血养血安神、助湿生痰的作用,可用于治疗脾胃虚弱、气血不足、倦怠懒动、惊悸怔肿、失眠健忘等证,达到健脾益胃、补气养血、养血安神、缓和药性的效果。而现代的药理学则发现,红枣含有蛋白质、脂肪、醣类、有机酸、维生素A、维生素C、微量钙、氨基酸等丰富的多种营养成分。枣能提高人体免疫力,并可抑制癌细胞:药理研究发现,红枣能促进白细胞的生成,降低血清胆固醇,提高血清白蛋白,保护肝脏,红枣中还含有抑制癌细胞,甚至可使癌细胞向正常细胞转化的物质。大枣含有大量的糖类物质,主要为葡萄糖,也含有果糖、蔗糖,以及由葡萄糖和果糖组成的低聚糖、***聚糖及半乳醛聚糖等;并含有大量的维生素C、核黄素、硫胺素、胡萝卜素、尼克酸等多种维生素,具有较强的补养作用,能提高人体免疫功能,增强抗病能力。大枣乙醇提取物对特异反应性疾病,能抑制抗体的产生,对小白鼠反应性抗体也有抑制作用,提示大枣具有抗***反应作用。
冰片(即龙脑):味辛、苦,性微寒,有开窍醒脑、清热明目、去翳等功能,内服可治热病神昏、惊痫癫狂、狂言乱语等证。采用冰片开窍醒神,清热止痛,引清热解毒药入归心经,防止热入心包出现窍闭神昏之症,引扶正药入脾、肺二经,发挥其扶正补虚之能。
巴豆:味辛,性热,能峻下胃肠中的寒积、腹水,具有通便的作用,并能治疗喉痹痰壅、肺痈痰多腥臭以及冷积凝滞所致的痢疾、泄泻等病证。含脂肪油Crothonoil约40~60%,油中含巴豆树脂,系巴豆醇、甲酸、丁酸及巴豆油酸结合而成的酯,有强烈的致泻作用。此外,含蛋白质约18%,其中包括一种毒性球蛋白,称巴豆毒素。另含有巴豆甙1~3.8%、精氨酸、赖氨酸、解脂酶及一种类似蓖麻碱的生物碱。其中,
巴豆提取物对小白鼠肉瘤S180实体型和S180腹水型,小白鼠***U14实体型和U14腹水型,以及艾氏腹水癌皆有明显的抑制作用,巴豆注射液在试管内有杀瘤细胞作用。巴豆醇二酯对小白鼠淋巴细胞性白血病P388有一定的抑制作用。巴豆油乳剂作大白鼠移植性皮肤癌内注射,能引起瘤体退化,并延缓皮肤癌的发展,因而认为巴豆中含有抗癌活性物质。另一方面,有促使肿瘤发生的作用:巴豆油及巴豆醇可促进致癌物质产生肿瘤。巴豆油虽无致癌作用,但与乌拉坦同用可引起皮肤***状瘤。巴豆油及其成分十四烷酰巴豆酯(teTCMLIBadecaoylphorbol)的乙酸盐可致小白鼠皮肤增生,巴豆醇酯C能改变小白鼠胚胎纤维母细胞膜的结构和通透性,这些变化都可能与促使肿瘤发生有关。巴豆油和牛的丙种球蛋白抗原一起给豚鼠注射,能抑制抗体的生成,并延迟对抗原的过敏反应,巴豆醇免疫抑制作用比巴豆油更强,此种免疫抑制作用亦可能是促使肿瘤产生的原因之一。也有人认为,促使肿瘤的发生可能与巴豆醇酯抑制细胞分化,能使鸟氨酸脱羧酶种纤维蛋白溶酶原活化剂升高等有着密切的关系。
败毒草(别名:耳形金毛裸蕨、石龙草、阴兜药、白带药、白马风、千屈菜):性微寒,味苦,含有牡荆素(vitexin)、荭草素(orientin)、异荭草素(isoorientin)、氯原酸、鞣花酸、没食子酸、胆碱、鞣质、色素、挥发油、果胶、树脂及生物碱等,可以去腐生肌、解毒、提高免疫力,燥湿止痒,用于风毒疮痒。
轻粉(别名:水银粉、汞粉、银粉):味辛,性寒而燥,轻粉主要含氯化亚汞(Mercurouschloride,Hg2Cl2),有攻毒去腐、杀毒止痒的作用,可用于治疗疮疡、梅毒、疥癣等病证,内对堇色毛癣菌、许兰黄癣菌、奥杜盎小芽胞癣菌、红色表皮癣菌、星形奴卡菌等皮肤真菌均有不同程度的抑制作用。
本发明的优点及有益效果是:
1、本发明中药组合物含有提高淋巴细胞数量的中药,如:黄芪、枸杞等,通过药物的联合配伍对HIV病毒实现多点杀灭,即中医理论所提出的散弹学说,同时增加淋巴细胞CD4数量和造血干细胞数量,达到免疫功能重建。
2、本发明中药组合物具有原材料资源丰富、便于收集、价格低廉、毒副作用小等优点,治疗成本低。不仅能使CD4淋巴细胞计数升高,提高AIDS患者的免疫功能,改善其生活质量,而且对HIV病毒具有一定的抑制作用,药效更全面。
3、本发明中药组合物毒副作用小,服用安全方便,能显著提高艾滋病、梅毒、吸毒患者的机体免疫力,降低外周血病毒载量,有效改善临床症状,控制病情发展,提高生活质量。
4、本发明中药组合物将防治感冒、咳嗽、发热,以及排毒、增加免疫力和增强体质相结合,攻补兼施,动静结合,升降相因,攻不伤正,补下留邪,气血津液兼顾,热、毒、湿、瘀、痰皆除,诸药共用,共同培元固本,益气生津,清热解毒,活血收湿之效,对早、中、晚期艾滋病、梅毒、吸毒患者,证属气虚血瘀,热毒内蕴的尤为适宜。
总之,现有技术中大多功能单一或效果不显著,本发明采用黄芪、桔梗、枸杞、红枣、冰片、巴豆、败毒草、轻粉组合为一个整体,相互之间配合使用,并且将多组配伍有机的结合,如:黄芪、冰片、巴豆、败毒草与轻粉配伍用于排毒、解毒,黄芪、枸杞、红枣与巴豆配伍用于增加免疫力,桔梗与冰片配伍用于防治感冒、咳嗽、发热。这样,通过杀灭血液细胞中病毒、提高人体抗体免疫力,有效地治疗艾滋病、梅毒、吸毒等,毒副作用小。
具体实施方式
实施例1
本实施例中,杀灭血液细胞中病毒、提高人体抗体免疫力的药物成分和含量如下:
黄芪150克;桔梗150克;枸杞150克;红枣150克;冰片200克;巴豆150克;败毒草150克;轻粉150克。
本实施例的药物用于治疗艾滋病,制作和使用方法如下:
将以上中药经研磨成粉末后,均匀混合,按5~7克揉捏制成药丸。口服每次12粒,间隔10日用药一次。
王某,男,47岁。因慢性间歇性腹泻、低热、干咳无痰、乏力等进行检测,被确诊为艾滋病病毒感染期,属献血感染。在感染后的一年多时间里,精神上出现了焦虑性障碍症,经常失眠多梦。有时甚至夜梦惊醒,浑身出汗,时间感到精神疲惫不堪,寝食难安,心烦狂躁。服用本实施例中药组合物6次,经四个月后,睡眠得到改善,体重开始增加,体力明显得到恢复。
李某,女,36岁。因慢性持续性腹泻、低热、厌食、乏力等进行检测,被确诊为艾滋病病毒感染期,属献血感染。在感染后的一年多时间里,身体瘦弱,心悸气短,精神萎靡,面容憔悴,经常感冒。服用本实施例中药组合物6次,经四个月后,慢性腹泻、低热等彻底消失,食欲明显增加,体质显著增强,没有发生感冒,体重开始增加,体力明显得到恢复。
为了验证本发明中药组合物的可行性和有效性,进行如下实验研究:
1、本发明中药组合物对HIV-I(I型人类免疫缺陷病毒,即I型艾滋病毒)、HIV-II(II型人类免疫缺陷病毒,即II型艾滋病毒)抑制作用的研究。实验证明:本发明中药组合物在体外细胞内对HIV-I和HIV-II均有明显的抑制作用。
2、本发明中药组合物最低抑菌浓度(MIC)的实验研究。实验证明:该药物对白色葡萄球菌、链球菌、痢疾杆菌和伤寒杆菌均有抑制作用。
3、本发明中药组合物对小白鼠免疫功能影响的实验研究,受试动物是6~8周龄、体重为18~22g、雌雄各半的小白鼠,随机分为三组,两组为对照组,一组为实验组。实验证明:当服用本发明中药组合物后,可以增强小白鼠非特异性免疫机能及细胞免疫、血液免疫功能。
4、本发明中药组合物急性毒性实验研究,受试动物是6~8周龄、体重为18~22g、雌雄各半的小白鼠,按临床用量(1.2g/kg)的100倍使用,最大耐受剂量(MTD)120g/kg。观察7天之后无一只死亡,且外观、行为、活动、摄食等无异常,动物未见明显毒副作用,从而证明急性毒实验的毒副作用小。
5、本发明中药组合物长期毒性实验研究,受试动物是6~8周龄、体重为80~90g、雌雄各半的大白鼠,按临床用量(1.2g/kg)的20倍使用。经过180天口服毒性试验,大白鼠各项指标、主要脏器系数、肉眼观察及镜下组织形态观察均无明显差异或异常,从而证明本发明中药组合物无明显毒性,按规定的剂量和疗程使用较为安全。
在动物实验的基础上进一步了临床实验研究,使用本发明中药组合物对10名艾滋病患者进行治疗。经过跟踪治疗,治疗结果如下:症状和体片得到明显的改善,体温恢复正常,腹泻停止,皮疹消散或明显减少,体重100%有所增加,平均增加5公斤,各项实验指标得到不同程序的改善。经过初步药效观察,本发明中药组合物可以提高艾滋病患者的机体免疫力,有效改善临床症状,控制病情发展,提高生活质量,毒副作用小,服用安全方便。对于HIV抗体呈阳性的艾滋病患者,在治疗前、治疗后(第4个月末)每个月检测一次,其免疫功能指标(CD4),疗效评定指标见表1。
表1
经过临床观察,在治疗前、治疗后(第4个月末)分别观察患者乏力、低热、消瘦、咳嗽、腹泻等症状,治疗结果如下:
(1)对乏力、低热、消瘦、咳嗽等症状有较好效果;
(2)对免疫***的影响,均比较稳定;
(3)精神感觉好,全身有劲,感冒次数减少,毒副作用小。
对于艾滋病患者来说,需要用药5~6次,经过一年后可治愈,呕吐、腹泻物为黑色。患者第一次服药和第二次服药后,呕吐、腹泻较重,***增大。第三次服药后,呕吐、腹泻减轻,身体逐渐脱落一层黑色薄皮,患者不痛不痒,***恢复正常大小,抗体免疫力明显增强。在用药六次后经过100天,皮肤恢复和正常皮肤一样有光泽,体力明显增强,体重可增加5~10公斤。对身体各个器官无损伤无副作用,可杀灭血液和细胞里的病毒。
实施例2
本实施例中,杀灭血液细胞中病毒、提高人体抗体免疫力的药物成分和含量如下:
黄芪150克;桔梗100克;枸杞200克;红枣150克;冰片200克;巴豆150克;败毒草150克;轻粉150克。
本实施例的药物用于治疗梅毒,制作方法如下:
将以上中药经研磨成粉末后,均匀混合,按5~7克揉捏制成药丸,口服每次12粒,间隔10日用药一次。
晚期梅毒与艾滋病有相似之处:
(1)均属于阳性;
(2)潜伏在人体的血液和细胞里;
(3)人体的抗体免疫力明显下降;
(4)均通过母婴、血液、性传播。
黄某,男,28岁。患湿性梅毒两年,全身长满毒疮,疼痛难忍,服用本实施例中药组合物三次后,经12个月治愈。
关某,男,35岁。患漏底梅毒一年,在患病期间,***红肿感染,***中部出现小孔,小便苦不堪言,服用本实施例中药组合物三次后,经12个月后治愈。
经过临床观察,本发明中药组合物可治疗上身梅毒,下肢梅毒,痤盘梅毒,干、湿两性梅毒,用药三次后,经12个月治愈,呕吐、腹泻物为绿色。头部出现米粒大小水泡,身体脱落一层少量黑皮,患者不痛不痒,半年后逐渐消失,皮肤恢复有光泽。
实施例3
本实施例中,杀灭血液细胞中病毒、提高人体抗体免疫力的药物成分和含量如下:
黄芪200克;桔梗150克;枸杞200克;红枣150克;冰片150克;巴豆150克;败毒草150克;轻粉150克。
本实施例的药物用于治疗吸毒,制作方法如下:
将以上中药经研磨成粉末后,均匀混合,按5~7克揉捏制成药丸。口服每次12粒,间隔10日用药一次。
丛某,男,22岁。在吸食***后,抑制了内源性阿片肽的生成,逐渐形成在***作用下的平衡状态,一旦停用就会出现不安、焦虑、忽冷忽热、起鸡皮疙瘩、流泪、流涕、出汗、恶心、呕吐、腹痛、腹泻等。为了避免戒断反应,就必须定时吸毒,并且不断加大剂量,使吸毒者终日离不开毒品。在服用本实施例中药组合物一次后,经3~6个月治愈,呕吐、腹泻物为黄色。
实施例结果表明,本发明采用黄芪、桔梗、枸杞、红枣、冰片、巴豆、败毒草、轻粉组合为一个整体,相互之间配合使用,通过杀灭血液细胞中病毒、提高人体抗体免疫力,可以有效地治疗艾滋病、梅毒、吸毒等疾病。
Claims (5)
1.一种杀灭血液细胞中病毒、提高人体抗体免疫力的药物,其特征在于,该药物的组成及含量为:
按重量份数计,黄芪1~5份;桔梗1~5份;枸杞1~5份;红枣1~5份;冰片1~5份;巴豆1~2份;败毒草1~2份;轻粉1~2份。
2.按照权利要求1所述的杀灭血液细胞中病毒、提高人体抗体免疫力的药物,其特征在于,该药物的组成及含量优选为:
按重量份数计,黄芪1~3份;桔梗1~3份;枸杞1~3份;红枣1~3份;冰片1~3份;巴豆1~2份;败毒草1~2份;轻粉1~2份。
3.按照权利要求1所述的杀灭血液细胞中病毒、提高人体抗体免疫力的药物,其特征在于,该药物用于治疗艾滋病,其组成及含量为:
按重量份数计,黄芪1~2份;桔梗1~2份;枸杞1~2份;红枣1~2份;冰片1~3份;巴豆1~2份;败毒草1~2份;轻粉1~2份。
4.按照权利要求1所述的杀灭血液细胞中病毒、提高人体抗体免疫力的药物,其特征在于,该药物用于治疗梅毒,其组成及含量为:
按重量份数计,黄芪1~2份;桔梗1份;枸杞1~3份;红枣1~2份;冰片1~3份;巴豆1~2份;败毒草1~2份;轻粉1~2份。
5.按照权利要求1所述的杀灭血液细胞中病毒、提高人体抗体免疫力的药物,其特征在于,该药物用于治疗吸毒,其组成及含量为:
按重量份数计,黄芪1~3份;桔梗1~2份;枸杞1~3份;红枣1~2份;冰片1~2份;巴豆1~2份;败毒草1~2份;轻粉1~2份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410064506.9A CN103768251B (zh) | 2014-02-24 | 2014-02-24 | 一种杀灭血液细胞中病毒、提高人体抗体免疫力的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410064506.9A CN103768251B (zh) | 2014-02-24 | 2014-02-24 | 一种杀灭血液细胞中病毒、提高人体抗体免疫力的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103768251A CN103768251A (zh) | 2014-05-07 |
CN103768251B true CN103768251B (zh) | 2016-06-01 |
Family
ID=50561311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410064506.9A Expired - Fee Related CN103768251B (zh) | 2014-02-24 | 2014-02-24 | 一种杀灭血液细胞中病毒、提高人体抗体免疫力的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103768251B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1621080A (zh) * | 2003-11-28 | 2005-06-01 | 罗建会 | 一种戒除毒瘾的药物及其制备方法 |
CN102210837A (zh) * | 2010-04-09 | 2011-10-12 | 肖嘉惠 | 治疗艾滋病的药物 |
CN102716326A (zh) * | 2012-07-04 | 2012-10-10 | 吴萍 | 一种增强免疫力的药物 |
-
2014
- 2014-02-24 CN CN201410064506.9A patent/CN103768251B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1621080A (zh) * | 2003-11-28 | 2005-06-01 | 罗建会 | 一种戒除毒瘾的药物及其制备方法 |
CN102210837A (zh) * | 2010-04-09 | 2011-10-12 | 肖嘉惠 | 治疗艾滋病的药物 |
CN102716326A (zh) * | 2012-07-04 | 2012-10-10 | 吴萍 | 一种增强免疫力的药物 |
Non-Patent Citations (4)
Title |
---|
"中医药在解毒治疗中的应用";朱一平;《时珍国药研究》;19970610;第8卷(第3期);第279-280页第1.1-1.2部分和第3部分 * |
"中草药治疗艾滋病研究进展";魏江玲;《哈尔滨医药》;20120825;第32卷(第4期);全文 * |
"梅毒的诊断与治疗";冯素华等;《中国医刊》;19991115;第34卷(第11期);第38页右列倒数第2段-第39页右列第1段 * |
"浅谈艾滋病的中医治疗";欧阳红;《中外医疗》;20071201;全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN103768251A (zh) | 2014-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102078520B (zh) | 一种治疗神经性头痛的中药制剂及其制备方法 | |
CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN103893722A (zh) | 一种治疗日光性皮炎的中药组合物及其制备方法 | |
CN102166278B (zh) | 一种治疗小儿类风湿性关节炎的中药组合物及其制备方法 | |
CN102058715B (zh) | 一种治疗慢性***炎的中药制剂及其制备方法 | |
CN104524287A (zh) | 一种治疗过敏性紫癜的中药组合物及其制备方法 | |
CN103041262B (zh) | 一种治疗慢性***炎的中药灌肠剂及其制备方法 | |
CN102847061B (zh) | 一种治疗小儿病毒性心肌炎的中药制剂及其制备方法 | |
CN112057501A (zh) | 用于治疗肌肉萎缩与肌无力的中药组合物、中药药膏及外用热敷膏药贴 | |
CN102178781B (zh) | 一种治疗阴囊湿疹的中药组合物及其制备方法 | |
CN105902827A (zh) | 提高人体免疫力的中药组合物及其制备方法 | |
CN104984296A (zh) | 一种治疗女性更年期综合症的药物组合物及其制备方法 | |
CN104547798A (zh) | 一种治疗慢性肠炎、阑尾炎的中药制剂及其制备方法 | |
CN103768251B (zh) | 一种杀灭血液细胞中病毒、提高人体抗体免疫力的药物 | |
CN103007145B (zh) | 一种治疗小儿轮状病毒肠炎的中药组合物及其制备方法 | |
CN113826882A (zh) | 防治糖尿病的膳食营养补充剂及其制备工艺 | |
CN105362630A (zh) | 一种治疗更年期综合症的药物组合物及其制备方法 | |
CN111084878A (zh) | 一种用于肺及呼吸***疾病的生物医药、医用全营养食品及制备方法 | |
CN105362629A (zh) | 一种含有杜仲的治疗女性更年期综合症的药物组合物及其制备方法 | |
CN104887950A (zh) | 一种治疗乳痈的中药组合物 | |
CN104840902A (zh) | 一种治疗卵巢肿瘤的中药制剂 | |
CN104162090B (zh) | 一种药物组合物及其制备方法 | |
CN108159389A (zh) | 一种用于治疗***炎的中药组合物及其制备方法 | |
CN114796434A (zh) | 内正邪不干丸 | |
CN101385838B (zh) | 一种用于治疗少***症的补肾生精制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160601 Termination date: 20190224 |